Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?

Table 3 Comparison of initial antimicrobial agents use in patients with non-ventilator and ventilator-associated hospital-acquired pneumonia

Main agents used	Group, n (%)		pValue
Main agents used	Non-ventilator associated (n = 48)	Ventilator-associated (n = 96)	pValue
Anti-pseudomonal penicillins^a	5 (10.4)	10 (10.4)	1.000
Anti-pseudomonal cephalosporins^b	12 (25.0)	18 (18.8)	0.514
Anti-pseudomonal fluoroquinolones^c	4 (8.3)	4 (4.2)	0.441
Anti-pseudomonal carbapenems^d	14 (29.2)	29 (30.2)	1.000
Ampicillin/sulbactam or sulbactam	5 (10.4)	13 (13.5)	0.789
Non-anti-pseudomonal β-lactamase^e	6 (12.5)	16 (16.7)	0.682
Miscellaneous^f	2 (4.2)	6 (6.3)	0.719

^aIncluding piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate.
^bIncluding cefoperazone, ceftazidime, cefepime, and cefpirome.
^cIncluding ciprofloxacin and levofloxacin.
^dIncluding imipenem and meropenem.
^eIncluding penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef.
^fIncluding teicoplanin or clindamycin plus amikacin.

ISSN: 1471-2334